Gadolinium Enhanced MR Coronary Vessel Wall Imaging at 3.0 Tesla.
Détails
Télécharger: 20981285_BIB_17B5D22698AD.pdf (6245.43 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_17B5D22698AD
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Gadolinium Enhanced MR Coronary Vessel Wall Imaging at 3.0 Tesla.
Périodique
Cardiology Research and Practice
ISSN
2090-0597
Statut éditorial
Publié
Date de publication
2010
Volume
2010
Pages
856418
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Purpose. We evaluated the influence of the time between low-dose gadolinium (Gd) contrast administration and coronary vessel wall enhancement (LGE) detected by 3T magnetic resonance imaging (MRI) in healthy subjects and patients with coronary artery disease (CAD). Materials and Methods. Four healthy subjects (4 men, mean age 29 ± 3 years and eleven CAD patients (6 women, mean age 61 ± 10 years) were studied on a commercial 3.0 Tesla (T) whole-body MR imaging system (Achieva 3.0 T; Philips, Best, The Netherlands). T1-weighted inversion-recovery coronary magnetic resonance imaging (MRI) was repeated up to 75 minutes after administration of low-dose Gadolinium (Gd) (0.1 mmol/kg Gd-DTPA). Results. LGE was seen in none of the healthy subjects, however in all of the CAD patients. In CAD patients, fifty-six of 62 (90.3%) segments showed LGE of the coronary artery vessel wall at time-interval 1 after contrast. At time-interval 2, 34 of 42 (81.0%) and at time-interval 3, 29 of 39 evaluable segments (74.4%) were enhanced. Conclusion. In this work, we demonstrate LGE of the coronary artery vessel wall using 3.0 T MRI after a single, low-dose Gd contrast injection in CAD patients but not in healthy subjects. In the majority of the evaluated coronary segments in CAD patients, LGE of the coronary vessel wall was already detectable 30-45 minutes after administration of the contrast agent.
Pubmed
Open Access
Oui
Création de la notice
17/02/2011 11:13
Dernière modification de la notice
09/08/2024 6:38